Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anal Cancer
New research on anal cancer from S.K. Mai and co-authors summarized
June 24th, 2008
"This retrospective study evaluated the efficacy, prognostic factors, and toxicity of combined radiochemotherapy for anal cancer. Data of 90 patients treated with radiochemotherapy between 1990 and 2006 were analyzed," researchers in Mannheim, Germany report. "Mean follow-up was 30 months (range: 2-129 months). Endpoints were disease-specific survival, local control, freedom from metastasis, and colostomy-free survival. Tumor stage, nodal status, age, sex, tumor site, tumor resection, and radiation dose were analyzed for prognostic value. Acute toxicity was scored according to the RTOG/EORTC scale, late toxicity according to the LENT/SOMA scale. Disease-specific...
Source: Cancer Weekly (2008-06-24)
|
